FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in ...
CURE21h
Overcoming Challenges and Advancing CAR-T Therapy for Myeloma
CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...
Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties
Under the terms of the agreement, Eagle will receive $69 million before transaction costs as an upfront payment in exchange for a prespecified amount of Eagle’s royalty interest for net sales of ...
AstraZeneca makes regulatory progress with Imfinzi, Calquence
AstraZeneca announced on Monday that it secured a US regulatory approval and a positive EU recommendation for two of its ...
pharmaphorum1d
Roche/AbbVie drug could further improve prognosis in CLL
Roche/AbbVie’s cancer drug venetoclax, which is set to become ... compared with standard bendamustine and Rituxan therapy. Results of MURANO published last week will form the basis of a ...
pharmaphorum2d
BeiGene's Brukinsa FDA approved for CLL/SLL
Beijing-based pharma, BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration ... or they received bendamustine plus rituximab (BR) for six cycles.
India Infoline3d
Natco Pharma Ltd Summary
It launched the Bendamustine Injection and Anastrozole ... It launched a first generic alternative to the cancer drug Pomalidomide capsules sold underthe Pomalyst brand; launched Apixaban ...
PharmiWeb5d
Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line mantle cell lymphoma
AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...